0.52 USD
▼-0.01-1.80%
盘后 0.55 0.00%
2026-09-16
市值
$8.19M
市盈率
—
EPS
-1.47
股息率
—
52 周区间
0.43 – 3.27
成交量
37.46K
Beta
1.60
目标价
1.00
52W 低 0.4352W 高 3.27
价格走势
公司简介
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib...